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C L I N I C A L C O M M E N TA R Y
Based on limited evidence, use of intra-
uterine devices (IUDs) is not contraindicated
for women with HIV/AIDS (strength of 
recommendation [SOR]: C), multiple sexual
partners (SOR: C), previous actinomyces
colonization (SOR: C), most types of
fibroids (SOR: C), or previous ectopic 
pregnancy (SOR: C).
The risk to IUD users of pelvic 
inflammatory disease (PID) is similar to
women using no contraception (SOR: B).
Nulliparous women may experience
increased insertion discomfort and higher
rates of expulsion (SOR: B). IUD use of 
<3.5 years is not associated with decreased
fertility (SOR: B).
IUDs are an excellent choice when
estrogens are contraindicated 
or adherence is an issue
One percent of contraceptive users in the
United States choose an IUD, compared
with 25% in Europe. This is partly due to
misinformation. An older IUD, the Dalkon
shield, had a braided polyfilament tail that
was associated with a higher risk of PID.
People in the US still associate IUDs with
this risk.
However, modern IUDs have a monofila-
ment tail, which has not been linked to
higher rates of PID. IUDs are an excellent
alternative when estrogens are contraindi-
cated, for prevention of pregnancy up to 5
days after unprotected sex, during lactation,
and when adherence to a contraceptive has
been difficult.
Shashi Mittal, MD
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❚ Evidence summary
IUDs are an effective and safe form of
contraception. However, many clinicians
have questions about the true contraindi-
cations to IUD use in the following situa-
tions. 
Infection. IUDs do not increase the
risk of complications among immunosup-
pressed HIV-positive women.1 IUD inser-
tion does not increase the risk of PID for
women with gonorrhea or chlamydia
infection compared with infected
nonusers.2 In one study, having multiple
sexual partners was not associated with
an increased risk of PID unless those part-
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ners carry specific infections, such as gon-
orrhea or chlamydia.3
In the US, approximately 1 in 1000
women develop PID after IUD insertion.3
Bacterial vaginosis may increase dysmen-
orrhea for women with IUDs (34.8 vs
13.9%, P=.03).4 In an observational
study, all of 7 women with actinomyces
who had IUDs removed remained nega-
tive for actinomyces after insertion of a
new IUD.5
Nulliparity and infertility. Nulliparous
women have increased rates of discomfort
with IUD placement (17.8% vs 8.8%) and
may have an increased risk of expulsion
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Significant uterine
enlargement can
increase the risk of
IUD expulsion
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(up to 18.5% in one study, compared
with less than 5.7% for all IUD users).6
Short-term (≤3.5 years) IUD use by nulli-
parous women was not associated with
decreased fertility in a case-control study;7
however, 1 cohort study demonstrated
lower fertility with use of a copper IUD
for longer periods: hazard ratio (HR):
0.69 (95% confidence interval [CI],
0.497–0.97) for 42–78 months; HR=0.50
(95% CI, 0.34–0.73) for >78 months.8
Uterine anomalies. Significant uterine
enlargement can increase the risk of IUD
expulsion (0 vs 4 women [13%]; P=.04 in
1 retrospective cohort study).9 There are
case reports of IUD failure and uterine
perforation among women with anom-
alies that distort the uterine cavity.10,11
Other. Some contraindications to IUD
use, such as concurrent pregnancy, are
obvious. Other common sense con-
traindications might include insertion by
patients with recent postpartum
endometritis, gynecologic malignancy,
genital bleeding of unknown cause, and
gestational trophoblastic disease. 
Recommendations from others
Manufacturer product labeling lists a num-
ber of contraindications. The American
College of Obstetrics and Gynecology and
the World Health Organization have simi-
lar but generally less restrictive lists of con-
traindications to IUD placement (TABLE). 
R E F E R E N C E S
1. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M,
Kokonya D. Complications of use of intrauterine devices
among HIV-1-infected women. Lancet 1998; 351:1238–1241.
2. Ryden G, Fahraeus L, Molin L, Ahman K. Do contraceptives
influence the incidence of acute pelvic inflammatory disease
in women with gonorrhoea? Contraception 1979;
20:149–157.
3. Steen R, Shapiro K. Intrauterine contraceptive devices and
TA B L E
ACOG WHO* MANUFACTURER
Uterine anomaly (including distension L, C L, C L, C
of uterine cavity)
History of PID L, C (past 3 L, C (current L (if no subsequent
mo only) PID only for both) pregnancy), C
Postpartum endometritis or septic L, C L, C (immediately L, C
abortion in the past 3 months post-septic abortion
for both)
Untreated cervicitis/vaginitis, L, C L, C (not bacterial L, C (including genital
including bacterial vaginosis vaginosis) actinomycosis)
Multiple sexual partners L, C (increased STI L, C
risk is a relative
contraindication
for both)
Immunosuppression L, C  (AIDS is a L, C
contraindication for
both, unless clinically
well on antiretroviral
therapy)
* Includes conditions rated as level 3 (risks usually outweigh benefits) or 4 (represents an unacceptable health risk) by WHO
L, levonorgestrel (Mirena) IUD; C, Copper T 380 (Paragard) IUD; IUD, intrauterine device; ACOG, American College of
Obstetricians and Gynecologists; WHO, World Health Organization; PID, pelvic inflammatory disease; STI, sexually transmitted
infection
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